Organization
Hospital of Prato
3 abstracts
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).Org: IRCCS Foundation National Cancer Institute, Milan, Italy, Molinette Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fondazione Policlinico Campus Bio-Medico, Orthopaedic Institute Rizzoli,